Haematologica, Vol 94, Issue 6, 827-832 doi:10.3324/haematol.2008.000935
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moscardó, F.
Right arrow Articles by Sanz, G. F.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Moscardó, F.
Right arrow Articles by Sanz, G. F.

Original Article

Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies

Federico Moscardó1, Jaime Sanz1, Leonor Senent1, Susana Cantero1, Javier de la Rubia1, Pau Montesinos1, Dolores Planelles2, Ignacio Lorenzo1, Jose Cervera1, Javier Palau1, Miguel A. Sanz1, Guillermo F. Sanz1

1 Department of Hematology, Hospital Universitario La Fe, Valencia
2 Centro de Transfusión de la Comunidad Valenciana, Valencia, Spain

Correspondence: Miguel A. Sanz, PhD, MD, Hematology Department, Hospital Universitario La Fe Valencia, Spain 46009 E-mail:sanz_mig{at}gva.es

Background: Cord blood transplant is a feasible treatment alternative for adult patients with hematologic malignancies lacking a suitable HLA-matched donor. However, the kinetics of myeloid recovery is slow, and primary graft failure cannot be detected easily early after transplantation. We investigated the impact of hematopoietic chimerism status from unselected marrow cells 14 days after transplantation on predicting engraftment after a cord blood transplant.

Design and Methods: Seventy-one adult patients with hematologic malignancies undergoing single-unit unrelated donor cord blood transplantation after a myeloablative conditioning regimen were included in the study. All patients received conditioning regimens based on busulfan, thiotepa and antithymocyte globulin. Chimerism status was assessed analyzing short tandem repeat polymorphisms.

Results: The cumulative incidence of myeloid engraftment at 1 month was significantly lower in patients with mixed chimerism than in those with complete donor chimerism (55% vs. 94%; p<0.0001). For patients achieving myeloid recovery, the median time of engraftment was 16 days when donor chimerism at day + 14 was higher than 90%, compared with 24 days when donor chimerism was below this level (p<0.001). A donor chimerism level of 65% was found to be the best cut-off point for predicting primary graft failure, with a sensitivity of 97% and a specificity of 80%. The incidence of primary graft failure was 67% for patients with less than 65% donor chimerism at day +14 as compared to only 2% for those with more than 65% donor chimerism (p<0.001). Patients with mixed chimerism also had a lower cumulative incidence of platelet engraftment than those with complete chimerism (62% vs. 89%; p=0.01).

Conclusions: Donor-recipient chimerism status at day +14 predicts engraftment after a single-unit cord blood transplant in adults.

Key words: hematopoietic chimerism, graft failure, engraftment, cord blood transplantation.